Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

NCT02713477 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010
DRUG: Insulin glargine HOE901
DRUG: Placebo

Sponsor

Sanofi